

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2011; month=4; day=11; hr=13; min=31; sec=23; ms=954;]

=====

Application No: 10591732 Version No: 1.0

Input Set:

Output Set:

Started: 2011-04-04 12:19:51.518
Finished: 2011-04-04 12:19:52.085
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 567 ms
Total Warnings: 5
Total Errors: 0
No. of SeqIDs Defined: 5
Actual SeqID Count: 5

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

SEQUENCE LISTING

<110> DAKE, MICHAEL D.
WAUGH, JACOB M.

<120> COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND
TRANSDERMAL DELIVERY OF BOTULINUM TOXINS

<130> 13720-105071US2

<140> 10591732
<141> 2011-04-04

<150> PCT/US05/07524
<151> 2005-03-03

<150> 60/550,015
<151> 2004-03-03

<160> 5

<170> PatentIn Ver. 3.5

<210> 1
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> misc_feature
<222> (1)..(20)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<221> misc_feature
<222> (21)..(45)
<223> This region may encompass 5, 7, 9, 11, 13, 15,
17, 19, 21, 23 or 25 "Arg" residues

<220>
<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 1
Gly
1 5 10 15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg
20 25 30

Arg
35 40 45

<210> 2
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(20)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<221> misc_feature
<222> (32)..(51)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 2
Gly
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly
35 40 45

Gly Gly Gly
50

<210> 3
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> misc_feature
<222> (1)..(20)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<221> misc_feature
<222> (32)..(51)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 3
Gly
1 5 10 15

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly
35 40 45

Gly Gly Gly
50

<210> 4
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(20)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<221> misc_feature
<222> (30)..(49)
<223> This region may encompass 0 to 20 "Gly" residues

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 4
Gly
1 5 10 15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
20 25 30

Gly
35 40 45

Gly

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5
Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg
1 5 10